245 related articles for article (PubMed ID: 10741731)
61. Immunohistochemical detection of p53 protein and prognosis of surgically resected non-small-cell lung cancer.
Quantin X; Pujol JL; Lehmann M; Simony J; Serre I; Michel FB
Cancer Detect Prev; 1997; 21(5):418-25. PubMed ID: 9307845
[TBL] [Abstract][Full Text] [Related]
62. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers.
Tammemagi MC; McLaughlin JR; Bull SB
Cancer Epidemiol Biomarkers Prev; 1999 Jul; 8(7):625-34. PubMed ID: 10428201
[TBL] [Abstract][Full Text] [Related]
63. [Correlation between RARbeta gene promoter methylation and P53 gene mutations in non-small cell lung cancer].
Tan C; Jin YT; Xu HY; Zhang CY; Zhang H; Zhang WM; Chen CM; Sun XY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Apr; 29(2):131-6. PubMed ID: 22487818
[TBL] [Abstract][Full Text] [Related]
64. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer.
Horio Y; Takahashi T; Kuroishi T; Hibi K; Suyama M; Niimi T; Shimokata K; Yamakawa K; Nakamura Y; Ueda R
Cancer Res; 1993 Jan; 53(1):1-4. PubMed ID: 8380124
[TBL] [Abstract][Full Text] [Related]
65. Distant metastases in ovarian cancer: association with p53 mutations.
Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
[TBL] [Abstract][Full Text] [Related]
66. Variation of p53 mutational spectra between carcinoma of the upper and lower respiratory tract.
Law JC; Whiteside TL; Gollin SM; Weissfeld J; El-Ashmawy L; Srivastava S; Landreneau RJ; Johnson JT; Ferrell RE
Clin Cancer Res; 1995 Jul; 1(7):763-8. PubMed ID: 9816043
[TBL] [Abstract][Full Text] [Related]
67. Clinical significance of p53 in non-small-cell lung cancer.
Komiya T; Hirashima T; Kawase I
Oncol Rep; 1999; 6(1):19-28. PubMed ID: 9864395
[TBL] [Abstract][Full Text] [Related]
68. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors.
D'Amico D; Carbone D; Mitsudomi T; Nau M; Fedorko J; Russell E; Johnson B; Buchhagen D; Bodner S; Phelps R
Oncogene; 1992 Feb; 7(2):339-46. PubMed ID: 1312696
[TBL] [Abstract][Full Text] [Related]
69. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies.
Casey G; Lopez ME; Ramos JC; Plummer SJ; Arboleda MJ; Shaughnessy M; Karlan B; Slamon DJ
Oncogene; 1996 Nov; 13(9):1971-81. PubMed ID: 8934544
[TBL] [Abstract][Full Text] [Related]
70. Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer.
Takahashi T; Sonobe M; Menju T; Nakayama E; Mino N; Iwakiri S; Nagai S; Sato K; Miyahara R; Okubo K; Hirata T; Date H; Wada H
J Surg Oncol; 2010 May; 101(6):500-6. PubMed ID: 20213688
[TBL] [Abstract][Full Text] [Related]
71. p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis.
Saitoh S; Cunningham J; De Vries EM; McGovern RM; Schroeder JJ; Hartmann A; Blaszyk H; Wold LE; Schaid D; Sommer SS
Oncogene; 1994 Oct; 9(10):2869-75. PubMed ID: 8084591
[TBL] [Abstract][Full Text] [Related]
72. p53 mutations in lung cancer following radiation therapy for Hodgkin's disease.
De Benedetti VM; Travis LB; Welsh JA; van Leeuwen FE; Stovall M; Clarke EA; Boice JD; Bennett WP
Cancer Epidemiol Biomarkers Prev; 1996 Feb; 5(2):93-8. PubMed ID: 8850268
[TBL] [Abstract][Full Text] [Related]
73. [Analysis of prognostic value of TP53 gene mutations in non-small cell lung cancer].
Szymanowska A; Jassem E; Dziadziuszko R; Skrzypski M; Kobierska-Gulida G; Holm K; Borg A; Rzyman W; Limon J; Jassem J
Pneumonol Alergol Pol; 2005; 73(3):264-9. PubMed ID: 16989164
[TBL] [Abstract][Full Text] [Related]
74. p53 status and its in vitro relationship to radiosensitivity and chemosensitivity in lung cancer.
Bergqvist M; Brattström D; Gullbo J; Hesselius P; Brodin O; Wagenius G
Anticancer Res; 2003; 23(2B):1207-12. PubMed ID: 12820372
[TBL] [Abstract][Full Text] [Related]
75. Polymorphisms of key chemokine genes and survival of non-small cell lung cancer in Chinese.
Ma H; Shu Y; Pan S; Chen J; Dai J; Jin G; Hu Z; Shen H
Lung Cancer; 2011 Nov; 74(2):164-9. PubMed ID: 21514686
[TBL] [Abstract][Full Text] [Related]
76. GPI-anchored molecule-like protein (GML) expression in non-small cell lung cancer (NSCLC).
Komiya T; Hirashima T; Kikui M; Fukuoka M; Ohno A; Kawase I
Anticancer Res; 1999; 19(5B):4315-9. PubMed ID: 10628393
[TBL] [Abstract][Full Text] [Related]
77. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.
Ichikawa A; Kinoshita T; Watanabe T; Kato H; Nagai H; Tsushita K; Saito H; Hotta T
N Engl J Med; 1997 Aug; 337(8):529-34. PubMed ID: 9262496
[TBL] [Abstract][Full Text] [Related]
78. Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data.
Lohmann D; Pütz B; Reich U; Böhm J; Präuer H; Höfler H
Am J Pathol; 1993 Mar; 142(3):907-15. PubMed ID: 8384408
[TBL] [Abstract][Full Text] [Related]
79. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Shigaki H; Baba Y; Watanabe M; Murata A; Ishimoto T; Iwatsuki M; Iwagami S; Nosho K; Baba H
Clin Cancer Res; 2013 May; 19(9):2451-9. PubMed ID: 23532889
[TBL] [Abstract][Full Text] [Related]
80. p53 and lung cancer.
Brambilla E; Brambilla C
Pathol Biol (Paris); 1997 Dec; 45(10):852-63. PubMed ID: 9769949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
